Barzolvolimab: A Novel Chance for Autoimmune Ailments? Barzolvolimab, a relatively identified medicinal agent, is creating considerable attention within the research sector. This groundbreaking protein functions as a powerful reducer of IL- 17F cytokine, a key factor in the pathogenesis of various chronic ailments, including IBD. Initial clinical